Latest Stock Buy or Sell? Make More Informed Decisions!

It reports Wednesday. Good risk/reward with shares rallying after an earnings beat but not declining much after a miss. They may buy Intel, which is rallying these days.

They reported a small top and bottom line miss, and cut their full-year forecast due to weakness in China. Shares ran up before the quarter, and sold off 3% after so is only -6.5%  from last month's all-time highs. A winner as central banks cut rates around the world.

Has excellent fundamentals across four businesses, including best-in-class medical devices renown in cardiology. However, they face lawsuits over their similac formula which studies show is not harmful. It's unfair. It lost a lawsuit last summer and was hit a $495 million penalty. More lawsuits are coming, though the latest decision yesterday went in Abbott's favour. Last month, federal agencies found that the formula is not at fault. Two weeks ago, ABT reported a clean top and bottom line beat and raised their full-year forecast. Shares would have rallied more without the lawsuits.

They aren't delivering on the things--vaccine results--they promise. He struggles with this stock.

One of the S&P's top stocks this year, and they just beat and raised.

A good company, but they design their products here, but make them in China. So if Trump wins, his tariffs will hurt this company, but is a must-buy if Harris wins.